Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
$4.22
-3.2%
$3.96
$2.24
$19.69
$195.49M2.81757,411 shs316,866 shs
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
$1.13
-3.0%
$1.01
$0.65
$1.75
$67.42M-0.02507,539 shs195,008 shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$12.97
-2.6%
$12.75
$6.43
$27.38
$163.27M0.43159,496 shs91,806 shs
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
$1.55
+2.6%
$1.50
$0.63
$1.91
$181.11M-0.05476,963 shs171,887 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
0.00%-1.40%+3.18%+37.91%-76.81%
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
0.00%0.00%+21.51%+48.70%+112,999,900.00%
Lifevantage Corporation stock logo
LFVN
Lifevantage
0.00%+7.99%+2.69%-3.43%+102.34%
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
0.00%+4.73%-3.13%+44.86%+91.36%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
2.4132 of 5 stars
3.33.00.00.01.81.70.6
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
1.3182 of 5 stars
3.50.00.00.00.60.00.6
Lifevantage Corporation stock logo
LFVN
Lifevantage
4.3154 of 5 stars
3.50.01.72.73.82.51.3
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
0.8102 of 5 stars
0.05.00.00.01.11.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
2.60
Moderate Buy$29.56600.37% Upside
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
3.00
Buy$7.33548.97% Upside
Lifevantage Corporation stock logo
LFVN
Lifevantage
3.00
Buy$30.50135.16% Upside
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest IRD, FDMT, TLSA, and LFVN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/12/2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (D-)
7/3/2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
6/27/2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (E+)
6/27/2025
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00
6/11/2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (D-)
5/24/2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
5/10/2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
5/9/2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$28.00 ➝ $25.00
5/9/2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$51.00 ➝ $44.00
5/9/2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$45.00 ➝ $38.00
4/24/2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (E+)
(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
$23K8,499.63N/AN/A$11.05 per share0.38
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
$10.99M6.13N/AN/A$0.21 per share5.38
Lifevantage Corporation stock logo
LFVN
Lifevantage
$200.16M0.82$0.88 per share14.71$2.05 per share6.33
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
N/AN/AN/AN/A$0.04 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
-$160.87M-$3.18N/AN/AN/A-767,126.06%-33.26%-30.68%8/6/2025 (Estimated)
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
-$57.53M-$2.10N/AN/AN/A-429.42%-283.28%-144.32%8/12/2025 (Estimated)
Lifevantage Corporation stock logo
LFVN
Lifevantage
$2.94M$0.6918.80N/A4.12%34.67%15.24%8/27/2025 (Estimated)
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
-$11.86MN/A0.00N/AN/AN/AN/A8/5/2025 (Estimated)

Latest IRD, FDMT, TLSA, and LFVN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
-$0.6922N/AN/AN/A$0.52 millionN/A
8/12/2025N/A
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
-$0.25N/AN/AN/A$4.27 millionN/A
5/15/2025Q1 2025
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
-$0.34-$0.32+$0.02-$0.24$4.00 million$4.30 million
5/8/2025Q1 2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
-$0.84-$0.86-$0.02-$0.86$0.53 millionN/A
5/6/2025Q3 2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.16$0.26+$0.10$0.26$60.99 million$58.44 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
N/AN/AN/AN/AN/A
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
N/AN/AN/AN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.181.39%N/A26.09%3 Years
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
N/AN/AN/AN/AN/A

Latest IRD, FDMT, TLSA, and LFVN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
quarterly$0.04501.5%5/30/20255/30/20256/13/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
N/A
12.36
12.36
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
N/A
1.98
1.98
Lifevantage Corporation stock logo
LFVN
Lifevantage
N/A
1.66
0.98
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
N/A
1.02
1.02

Institutional Ownership

CompanyInstitutional Ownership
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
99.27%
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
14.97%
Lifevantage Corporation stock logo
LFVN
Lifevantage
35.32%
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
N/A

Insider Ownership

CompanyInsider Ownership
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
9.60%
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
6.60%
Lifevantage Corporation stock logo
LFVN
Lifevantage
20.65%
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
39.82%
CompanyEmployeesShares OutstandingFree FloatOptionable
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
12046.33 million41.88 millionOptionable
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
1459.66 million55.72 millionN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
26012.59 million9.99 millionOptionable
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
8116.85 million70.32 millionOptionable

Recent News About These Companies

Tiziana Life Sciences Ltd (TLSA) - Yahoo Finance
Why Tiziana Life Sciences Ltd (TLSA) is Surging in 2025

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
4D Molecular Therapeutics stock logo

4D Molecular Therapeutics NASDAQ:FDMT

$4.22 -0.14 (-3.21%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$4.22 0.00 (-0.12%)
As of 07/18/2025 06:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Opus Genetics stock logo

Opus Genetics NASDAQ:IRD

$1.13 -0.04 (-3.00%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$1.15 +0.02 (+2.12%)
As of 07/18/2025 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.

Lifevantage stock logo

Lifevantage NASDAQ:LFVN

$12.97 -0.34 (-2.55%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$12.96 -0.01 (-0.04%)
As of 07/18/2025 07:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

Tiziana Life Sciences stock logo

Tiziana Life Sciences NASDAQ:TLSA

$1.55 +0.04 (+2.65%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$1.49 -0.06 (-3.81%)
As of 07/18/2025 07:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.